High Throughput Screening Market

The global high throughput screening market in terms of revenue was estimated to be worth $25.7 billion in 2023 and is poised to reach $44.5 billion by 2028, growing at a CAGR of 11.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of this market is majorly driven by growing adoption of high-throughput screening techniques in drug discovery, rising incidence of cancer, and growing availability of funds for research. On the other hand, the high cost of high-throughput screening systems is restraining the growth of this market.

High-Throughput Screening (HTS) Market- Global Forecast to 2028

To know about the assumptions considered for the study, Request for Free Sample Report

High Throughput Screening Market

DRIVER: The growing adoption of open innovative models in pharmaceutical & biotechnology companies

Open innovation refers to the practice of leveraging external ideas, technologies, and collaborations to accelerate innovation and overcome research and development challenges. Open innovation models enable pharmaceutical and biotech companies to collaborate with academic institutions, research organizations, and technology providers. This collaboration allows companies to tap into external expertise and gain access to novel technologies and approaches in HTS. By leveraging a broader knowledge base, companies can enhance their screening capabilities and improve the efficiency of drug discovery processes. Overall, the adoption of open innovative models in the pharmaceutical and biotech industries can drive the HTS market by providing access to external expertise, accelerating drug discovery, expanding compound libraries, sharing costs and risks, facilitating cross-disciplinary collaboration, and enabling access to new technologies.

RESTRAINT: The capital-intensive nature of HTS instruments

HTS instruments, such as automated liquid handling systems, robotic arms, microplate readers, and high-resolution imaging systems, require significant upfront investment. The cost of acquiring and setting up these instruments can be substantial, making it a barrier for smaller research organizations, academic institutions, and startups with limited budgets. The high initial investment can limit access to HTS technologies and slow down their adoption. In addition to the initial investment, HTS instruments often entail ongoing operational costs. These costs include maintenance, calibration, supplies, reagents, and consumables required for the screening process. These expenses can accumulate over time, and organizations need to allocate resources to cover them.

OPPORTUNITY: Increasing adoption of high-throughput screening technologies in emerging markets

Emerging markets like China, India, and Brazil have experienced rapid expansion in the life science and biotechnology sectors in recent years. These regions have a significant pool of talented researchers, physicians, and scientists who are actively pursuing research in these fields. Additionally, government initiatives in emerging markets play a crucial role in promoting the adoption and development of HTS technologies. Governments can establish regulatory frameworks and guidelines to ensure the safe and ethical use of HTS technologies.

CHALLENGE: Complexity in data analysis and management

With the enormous amount of data generated from HTS experiments, there is a need for robust data management systems to handle data storage, organization, and retrieval. Additionally, data integration from various sources, such as chemical databases or genomic data, requires standardized formats and interoperability. Data quality control is crucial to ensure the reliability and accuracy of HTS data, requiring validation and normalization procedures.

Global High-Throughput Screening (HTS) Ecosystem Analysis

The ecosystem for HTS consists of pharmaceutical & biotechnology companies, HTS service providers (screening services), instrument & reagent suppliers, academic & research institutions, technology providers, data management & analysis providers, regulatory authorities (ensuring compliance and safety), and collaborative networks promoting knowledge sharing and collaboration. These stakeholders interact and collaborate to drive the advancement of HTS technologies, enhance drug discovery processes, and develop new therapeutics.

The consumables segment dominated high throughput screening industry by product & service:

Based on product & service, the high throughput screening market is segmented into consumables, instruments, services, and software. The consumables segment accounted for the largest share of the global market in 2022. This segment's large share can be attributed to factors such as wide used of reagents & assay kits used in HTS techniques, increasing pharmaceutical R&D, and increasing government funding for life sciences research.

To know about the assumptions considered for the study, download the pdf brochure

The Asia Pacific region catered the fastest growth of the high throughput screening industry in 2022.

In 2022, Asia Pacific region accounted for the fastest-growing region of the high throughput screening market. It is also estimated to grow at the highest CAGR in the market during the forecast period, this is mainly due to factors such as the rising R&D spending, rising prevalence of chronic diseases and the need for effective disease monitoring and drug development and the growing trend of outsourcing drug discovery services.

Key Market Players

Key players in the high throughput screening market include Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Danaher Corporation (US), PerkinElmer, Inc. (US), Tecan Trading AG (Switzerland), AXXAM S.p.A (Italy), Promega Corporation (US), Bio-Rad Laboratories, Inc.(US), Promega Corporation (US), Hamilton Company (US), Corning Incorporated (US), Charles River Laboratories (US), Lonza (Switzerland), REPROCELL Inc. (Japan), Aurora Biomed (Canada), BMG LABTECH (Germany), DIANA Biotechnologies, s.r.o. (Czech Republic), NanoTemper Technologies GmbH (Germany), Creative Biolabs (US), Biomat Srl (Italy), HighRes Biosolutions (US), Cyclica Inc. (Canada), Crown Bioscience (US), and Sygnature Discovery (UK).

Scope of the High Throughput Screening Industry

This report categorizes the high throughput screening market to forecast revenue and analyze trends in each of the following submarkets:

By Product & Service

• Consumables
  • Reagents & Assay Kits
  • Laboratory Equipment
• Instruments
  • Liquid Handling Systems
  • Detection Systems
  • Other Instruments
• Services
• Software

By Technology

• Cell-based Assays
  • 2D Cell Culture
  • 3D Cell Culture
    • Scaffold-based Technology
      • Hydrogels
        • Animal-derived Hydrogels
          • Matrigel
          • Collagen
        • Synthetic Hydrogels
        • Alginate/Agarose
      • Inert Matrix/Solid Scaffolds
      • Micropatterned Surfaces
    • Scaffold-free Technology
      • Ultra-low Binding Plates
      • Hanging-drop Plates
      • Other Scaffold-free Technologies
  • Reporter-based Assays
  • Perfusion Cell Culture
• Lab-on-a-Chip Technology (LOC)
• Label-free Technology

By Application

• Drug Discovery
• Biochemical Screening
• Life Sciences Research
• Other Applications

By End User

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • China
  • India
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • RoLATAM
• Middle East and Africa (MEA)

Recent Developments of High Throughput Screening Industry

• In February 2023, Agilent Technologies, Inc. launched the on-deck thermal cycler that integrates with the Agilent Bravo NGS automated liquid handling platform.
• In February 2023, PerkinElmer Inc. launched the Multimode Plate Reader for high-throughput screening (HTS) applications and to accelerate drug discovery efforts.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst